








1Department of Pediatric Nephrology, 
and hypertension, jagiellonian university 
Medical college, cracow, Poland
head:
Prof. Dorota Drożdż, MD, PhD.
2semmelweis university, 3rd Department 
of internal Medicine, research laboratory 
and Füst györgy complement Diagnostic 
laboratory, Budapest, hungary
head:
Prof. zoltán Prohászka, MD, Dsc
address for correspondence: 
Monika Miklaszewska
wielicka st. 265, 30-663 krakow, Poland
e-mail: mmiklasz@wp.pl
prace  oryginalne
Significance of complement system 
diagnostics in thrombotic microangiopathies
Znaczenie diagnostyki układu dopełniacza 
w przebiegu mikroangiopatii zakrzepowych
Thrombotic microangiopathies 
(TMA) are rare life threatening dis-
eases of various etiologies, making 
the identification of the specific forms 
and appropriate treatment difficult. 
The pathophysiology-based classifi-
cation of various TMAs is important 
in making clinical decisions and plan-
ning the therapy outline. Detailed di-
agnostic management of the comple-
ment system, occasionally extended 
to include genetic workup is generally 
recommended in all TMA cases, as it 
allows for an individualized mode of 
treatment planning, estimates the 
prognosis and risk of disease recur-
rence, which is demonstrated by new 
HUS case reports cited in the current 
survey. In the paper, there are pre-
sented six cases of non-Shiga-toxin 
HUS including: two cases of aHUS 
caused by autoantibody against fac-
tor H (DEAP-HUS), aHUS caused by 
DGKE mutation, aHUS caused by 
MCP mutation, HUS caused by Strep-
tococcus pneumoniae, and HUS sec-
ondary to Escherichia coli sepsis. In 
all the presented cases, the detailed 
complement system diagnostic and 
in five - also genetic workup were per-
formed. The complexity of TMA, and 
the importance of complete differen-
tial diagnostic workup of all non-Shi-
ga-toxin HUS cases due to the risk of 
developing CKD or ESKD, the risk of 
aHUS relapse both in native or trans-
planted kidneys, and to potential pro-
longed eculizumab treatment is high-
lighted by the current case reports.
Mikroangiopatie zakrzepowe (thro-
-mbotic microangiopathies - TMA) 
są to rzadkie zagrażające życiu cho-
roby o zróżnicowanej etiologii, co 
powoduje, że identyfikacja poszcze-
gólnych postaci oraz właściwe ich 
leczenie jest trudne. Szczegółowa 
diagnostyka układu dopełniacza 
czasami wzbogacona o diagnosty-
kę genetyczną jest zasadniczo za-
lecana we wszystkich przypadkach 
TMA, gdyż umożliwia zindywiduali-
zowanie planu leczenia, oszacowa-
nie rokowania oraz ryzyka nawrotu 
choroby, co zostało zobrazowane na 
przykładzie zamieszczonych opisów 
przypadków TMA u naszych pacjen-
tów. W pracy przedstawiono sześć 
przypadków zespołu hemolityczno 
– mocznicowego (hemolytic uremic 
syndrome - HUS) nie związanego 
z zakażeniem bakteriami produku-
jącymi Shigatoksynę - w tym:  dwa 
przypadki atypowego HUS (aHUS) 
wywołanego obecnością przeciw-
ciał przeciwko czynnikowi H (DEAP-
-HUS); przypadek aHUS wywołane-
go mutacją w genie diacyloglicerolu 
epsilon (DGKE); przypadek aHUS 
wywołanego mutacją w genie błono-
wego kofaktora białkowego (mem-
brane cofactor protein – MCP); przy-
padek HUS wywołanego zakażeniem 
Streptococcus pneumoniae (Strep-
-HUS) oraz przypadek HUS wtórne-
go do posocznicy wywołanej przez 
Escherichia coli. U wszystkich dzie-
ci została przeprowadzona szcze-
gółowa diagnostyka układu dopeł-
niacza; natomiast u piątki z nich 
– również diagnostyka genetyczna. 
Na przykładzie zamieszczonych opi-
sów przypadków przedstawiono zło-
żoność patogenezy TMA oraz zna-
czenie przeprowadzenia diagnostyki 
różnicowej we wszystkich przypad-
kach HUS nie związanych z Shiga-
toksyną, głównie z uwagi na istotne 
ryzyko wystąpienia przewlekłej lub 
schyłkowej niewydolności nerek, 
nawrotu aHUS w nerce własnej lub 
przeszczepionej jak i do potencjal-
nej przewlekłej terapii eculizuma-
bem.      
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Background 
Thrombotic microangiopathies (TMa) 
are rare life threatening diseases of various 
etiologies, making the identification of the 
specific forms and appropriate treatment 
difficult. The etiology and pathophysiolo-
gy-based classification of various TMas is 
important to making clinical decisions and 
planning the therapy outline. 
clinical features that define hemolytic 
uremic syndrome (hus) include the pre-
sence of acute kidney injury (aki), signs of 
microangiopathic hemolytic anemia (eleva-
tion of lactate dehydrogenase - lDh, de-
creased haptoglobin and presence of frag-
mented red cells in the blood smear) and 
acute thrombocytopenia [1].
The majority of cases of pediatric 
hus (90%) are associated with diarrhea 
and bacterial infections (such as entero-
pathogenic escherichia coli – ePec or 
shigella dysenteriae) secreting shiga-like 
toxins that provoke significant endothelial 
damage (shiga toxin - hus). less frequ-
ently, hus may also occur as a complica-
tion of various other infectious etiologies 
(e.g.: streptococcus pneumoniae hus / 
strep-hus, influenza a / h1N1-hus) or 
be secondary to coexisting diseases (e.g.: 
bone-marrow and solid organ transplanta-
tion, malignancies, autoimmune disorders, 
antiphospholipid syndrome, some drugs, 
malignant hypertension, hiV infection) [2]. 
according to the international con-
sensus, the term of atypical hus (ahus) 
should be nowadays reserved for patients 
with hus without any coexisting disease 
[2]. This means that in clinical practice, 
ahus cases are limited to dysregulation of 
the alternative complement pathway (aP) 
hus, mutations in the complement ge-
nes encoding membrane cofactor protein 
(McP, cD46), c3, factor i (cFi), factor B 
(cFB), factor h (cFh), factor h related pro-
teins 1-5 (cFhr 1-5) and thrombomodulin 
(ThBD) or to the presence of auto-antibo-
dies against factor h [2]. excessive com-
plement activation may be caused by ga-
in-of-function in complement factors (due 
to genetic mutations) or loss-of-function in 
complement regulatory proteins (caused 
by genetic mutations or auto-antibodies). 
approximately 60% of ahus cases are dia-
gnosed with a molecular aP abnormalities 
[3,4,5]. other more rare factors, such as 
diacylglycerol kinase-epsilon (Dgke) mu-
tations, and plasminogen (Plg) mutations 
have been also recently described as risk 
factors for the development of ahus [6].
Thrombotic thrombocytopenic purpu-
ra (TTP) caused either by a severe con-
genital deficiency in metalloproteinase 
aDaMTs13 or by the acquired presence of 
anti-aDaMTs13 antibodies, should not be 
classified as ahus, but has to be included 
in the differential diagnosis as an entity that 
has to be ruled out in patients suspected to 
have ahus in the first sequence.
summing up, the preceding data prove 
that the exact diagnosis of ahus is particu-
larly challenging, and mainly based on the 
exclusion of various clinical conditions and 
diseases, especially if ahus triggering fac-
tors, such as various infections, are also si-
multaneously present. The following cases 
presentation exemplifies this difficult topic, 
underlying the necessity and importance of 
the requirement for full differential diagno-
stic workup, including genetic investiga-
tions of all ahus cases, mainly after taking 
under consideration the fact that treatment 
modalities in particular cases may be signi-
ficantly different.
Detailed diagnostic management of the 
complement system occasionally extended 
to include genetic workup is generally re-
commended in all non-shiga toxin-caused 
hus cases, as it allows for individualized 
mode of treatment planning, estimates 
the prognosis and risk of disease recur-
rence, which may be demonstrated ba-
sed on the new case reports cited in the 
current survey. 
in the first large series of patients with 
anti-complement factor h (cFh) antibo-
dies-associated ahus and deficiency of 
cFhr proteins antibody positive hus 
(DeaP-hus), the authors reported a poor 
outcome including death (9%), frequent 
relapses (58%), chronic kidney disease 
(ckD) in 39% and end-stage kidney dise-
ase (eskD) in 27% after a mean follow up 
of 39 months [2]. however, in a recent co-
hort of children with this form of ahus who 
were treated early with therapeutic plasma 
exchange (TPe), immunosuppressive me-
dications and glucocorticosteroids (gcc), 
the outcome was much more favorable [7].
Material and Methods
in the current article we presented six 
cases of non-shiga-toxin hus including: 
two cases of ahus caused by autoantibo-
dy against factor h (DeaP-hus), ahus 
caused by Dgke mutation, ahus caused 
by McP mutation, hus caused by strepto-
coccus pneumoniae, and hus secondary 
to escherichia coli sepsis.
in our center there were three cases of 
DeaP-hus that resulted in entirely diffe-
rent epilogues. 
The first one from 2008 (a 7-year-old 
girl) ended up with eskD within seven we-
eks from the onset of the disease. after 
two years of peritoneal dialysis (PD), prior 
to renal transplant (rT) preparation, the 
detailed diagnostic management confir-
med DeaP-hus and a proper treatment 
(TPe, mycophenolate mofetil - MMF, in-
travenous immunoglobulin-iVig) made 
the whole transplantation procedure suc-
cessful. The detailed information concer-
ning this case is presented in publication 
by grenda et al. [8]. 
in the current report, we present two 
new cases of DeaP-hus that were mana-
ged in our center eight years later. The first 
one was a ten-year-old previously healthy 
boy (PP) who was admitted to our Depart-
ment with signs and symptoms of nephri-
tic-nephrotic syndrome (blood urea nitro-
gen – BuN: 8.3 mmol/l, serum creatinine 
– scr: 76.3 umol/l, cystatin c: 1.27 mg/l; 
estimated glomerular filtration rate -  egFr 
(schwartz 2009): 58.8 ml/min/1.73 m2, 
proteinuria: 2.14 g/l, erythrocyturia: 10-25 
rBc/hpf); his detailed immunological dia-
gnostics was within normal ranges, blood 
pressure (BP) was elevated, renal usg 
was normal. During the following three 
months, the renal parameters returned to 
normal ranges and proteinuria receded wi-
thout any treatment. six months after the 
first episode, during viral respiratory tract 
infection, the patient was admitted to hospi-
tal with signs and symptoms of hus (BuN: 
52.1 mmol/l, scr: 390.3 umol/l, lDh: 3611 
u/l, hemoglobin - hb: 63 g/l, platelet num-
ber: 17.000/ul, proteinuria: 11.9 g/l, erythro-
cyturia: 80-120 rBc/hpf, direct antiglobulin 
test: negative), with oliguria (which lasted 
three days) and elevated BP. in initial com-
plement evaluation only c3c was slightly 
decreased (0.7 g/l, ref. 0.9-1.8 g/l), where-
as aP components and regulators were wi-
thin the reference ranges. The patient was 
treated with a single hemodialysis session 
(hD) and (in total) with 7 TPe sessions, 
with a very good response within nine days, 
namely, his renal, hemolysis and complete 
blood count (cBc) parameters returned to 
the normal ranges. however, there was still 
nephrotic range proteinuria (12-17 g/l) per-
sisting. in kidney biopsy performed during 
the second week of hospitalization - in light 
microscopy, the picture looked more like 
membranoproliferative glomerulonephritis 
- MPgN (glomerular lobulation, thickened 
capillary walls with double contouring), 
however, in electron microscopy, it looked 
more like TMa (rareness of lamina densa, 
podocytes foot processes effacement, en-
dothelium edema). in detailed complement 
assessments, it was demonstrated that the 
patient had a positive titer of anti-cFh igg 
auto-antibodies (218 au/ml, ref.<110), 
a low level of factor h (71, ref. 250-880 
mg/l), and signs of aP activation (a low le-
vel of c3c: 0.64 g/l), total aP complement 
activity: 55 % (ref. 70-105%). genetic as-
sessment showed homozygous deletion of 
the cFhr1 gene (DeaP-hus), and hete-
rozygous deletion of the cFhr3 gene. Due 
to suspicion of MPgN, the treatment with 
high doses of methylprednisolone - MP (15 
mg/kg) and an intravenous cyclophospha-
mide (cP) course (500 mg/m2)  were initia-
ted, and due to high BP - amlodipine was 
administered. The control complement re-
sults obtained two weeks afterwards con-
firmed the efficacy of the employed thera-
py, proving the disappearance of anti-cFh 
auto-antibodies and an increase of factor 
h level (287 mg/l). The renal parameters 
were normalized within two weeks, the pro-
teinuria completely receded within four we-
eks. The patient is currently in a very good 
clinical condition, with negative anti-cFh 
auto-antibodies (102 au/ml). The planned 
treatment includes six cP pulses and then 
under the anti-cFh auto-antibodies titer 
guidance – conversion into mycophenolate 
mofetil and gradual reduction of gcc. 
The third DeaP-hus case was an 
eight-year-old previously healthy boy (js), 
who was admitted to our Department from 
a local hospital with signs and symptoms 
of hus (oliguric, severely dehydrated, with 
yellow skin color, covered with numerous 
petechiae, BuN: 37.5 mmol/l, scr: 238.5 
umol/l, cystatin c: 3.61 mg/l, lDh: 6482 
u/l, hb: 68 g/l, platelet count: 23.000/ul, 
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proteinuria 3.29 g/l, erythrocyturia: 50-80 
rBc/hpf). his renal usg showed hypere-
chogenic, enlarged kidneys. in his medical 
history there were numerous severe episo-
des of vomiting after eating a hamburger in 
a local restaurant, but without diarrhea. The 
patient was treated with 3 hD sessions and 
(in total) with 9 TPe sessions, with a good 
response after the second TPe session – 
his renal, hemolysis and cBc parameters 
returned to the normal ranges. in detailed 
complement assessments, it was demon-
strated that the patient had a positive titer 
of anti-cFh igg auto-antibodies (1161 au/
ml, ref.<110), a low level of factor h (78, 
ref. 250-880 mg/l) and signs of aP activa-
tion (a low level of c3c: 0.86 g/l). genetic 
assessment showed homozygous deletion 
of the cFhr1 gene, heterozygous dele-
tion in exons 1-3  in both the cFhr3 and 
cFhr4 genes, and cD46 variations that 
are constituents of the McPggaac risk ha-
plotype. in kidney biopsy performed during 
the third week of hospitalization - in light 
microscopy, the picture looked more like 
MPgN (thickened capillary walls with do-
uble contouring, mesangial proliferation), 
however in electron microscopy, the pictu-
re was non-characteristic. Due to anti-cFh 
auto-antibodies ahus - MP (15 mg/kg) and 
intravenous cP courses (750 mg/m2) were 
initiated. six weeks after the first symp-
toms of hus, the renal parameters were 
within the normal limits; however there is 
still nephrotic range proteinuria (around 1 
g/l) and hypertension requiring high doses 
of angiotensin converting enzyme inhibitor 
(acei), but the patient is currently in a very 
good clinical condition. The planned treat-
ment includes six cP pulses and then un-
der the anti-cFh auto-antibodies titer gu-
idance – conversion into MMF and gradual 
reduction of gcc. 
in the 2nd and 3rd case, the patients’ 
native kidneys were saved and their func-
tion is so far absolutely normal. This vast 
difference is a result of not only better un-
derstanding the pathology of the disease, 
but also of the better access to specific 
diagnostics.       
in approximately 10-15% of patients 
with ahus, there are mutations of trans-
membrane complement alternative path-
way regulator – membrane cofactor protein 
(McP, cD46). McP is expressed on the 
surface of most nucleated cells, including 
the kidney and endothelial cells, and pro-
tects cells from complement damage. in 
addition, McP fulfills important roles in 
regulating various immune functions and 
acts as a receptor for various pathogens. 
McP binds c3b through its extracellular 
domains, and acts as a cofactor of factor 
i in the proteolytic inactivation of c3b into 
ic3b [1,2]. age at onset of ahus in case 
of McP mutations is usually above the 1st 
year of life [7].
in our center, there were two cases of 
McP mutation, which finales were totally 
diverse.
The first one was a five-year-old girl 
(Mj) admitted to our Department with 
signs and symptoms of hus (BuN: 20 
mmol/l, scr: 577 umol/l, lDh –2974 u/l, 
proteinuria: 2.6 g/l, erythrocyturia: field 
covered with red blood cells), with no pre-
ceding diarrhea, but with a positive histo-
ry of viral respiratory tract infection. one 
TPe and 5 hD sessions were performed. 
The complement (c3c, c4) and other im-
munological tests were normal. Due to the 
severe hypertension and cardiac failure, 
the antihypertensive medications were in-
itiated. The first kidney biopsy did not con-
firm hus. The kidney function improved, 
but the hypertension persisted. Two years 
later, hypertension emergency with neuro-
logical symptoms was diagnosed and she 
required treatment in the pediatric intensi-
ve care unit (Picu). egFr decreased to 50 
ml/min/1.73m2. The second kidney biopsy 
revealed vascular changes of thickened 
capillary walls and 50% of sclerotic glome-
ruli. The patient’s nephrological follow-up 
visits were subsequently very irregular. se-
ven years later, she was again admitted to 
Picu with eskD, cardiac failure and cho-
rioretinitis. The hD sessions and pleural 
drainage were necessary. in the third kid-
ney biopsy, vascular changes of thickened 
capillary walls and narrowed blood vessels 
were found again. in the immunological 
tests, the p-aNca titer was positive, but 
the complement levels were within normal 
ranges. The gcc therapy did not improve 
the kidney function and that is why chronic 
hD therapy was initiated, during which she 
presented with severe hypertension despi-
te intensive antihypertensive therapy. Due 
to refractory hypertension, she had bilate-
ral nephrectomy performed. The genetic 
investigation revealed a heterozygous mu-
tation (p.Pro155leu) in exon 4 of the cD46 
gene. Neither mutation in factor h nor anti 
cFh antibody presence was noted. after 
14 months on hD, she was successfully 
transplanted from a cadaveric donor. There 
were no more hus recurrences observed 
later in her follow up.
on the other hand, in the second case 
(MB) that was treated fifteen years later 
(the detailed description by Miklaszewska 
et al. [1]), where a new mutation in the 
cD46 gene was demonstrated and the 
ahus case was triggered by Mycoplasma 
pneumoniae infection, the patient remains 
in a very good clinical condition with no re-
nal sequelae. 
although complement abnormalities 
are typical in ahus, the normal comple-
ment profile does not exclude the possibi-
lity of ahus. lemaire et al. reported that 
recessive mutations in the gene encoding 
for diacylglycerol kinase epsilon (Dgke) 
cause ahus [9]. Dgke is a protein of the 
lipid kinase family expressed in the endo-
thelium, platelets and podocytes, which 
has been identified in an autosomal reces-
sive form of ahus occurring in the first year 
of life [9,10,11]. The mechanism of hus in 
Dgke mutation is most likely related to 
the activation of protein kinase c due to 
the loss of function of Dgke, leading to an 
upregulation of prothrombotic factors and 
platelet activation [12]. 
Below, we present a case of Dgke 
gene mutation which is considered functio-
nally relevant as most probably no active 
Dgke protein is produced by the cells of 
the patient. a five-month-old previously 
healthy girl (MP) born of healthy unrelated 
parents, was admitted to Picu with signs 
of TMa and aki requiring PD after an epi-
sode of non-bloody diarrhea. in the medi-
cal history, there had been loss of appetite, 
somnolence, fever and a few episodes of 
vomiting continued for three days. on ad-
mission to Picu, she was in a severe ge-
neral condition, anuric, with very high blood 
pressure values and numerous petechiae. 
chest X-ray demonstrated severe pneu-
monia; in the tracheal-bronchial aspirate, 
klebsiella pneumoniae was cultured. in the 
laboratory tests there were signs sugge-
stive of hus (scr: 336 umol/l, hb: 63 g/l, 
platelet number: 20.000 / ul, lDh: 11994 
u/l, direct antiglobulin test – negative, pro-
teinuria: 25.2 g/l, erythrocyturia: 100 rBc/
hpf). in the initial complement evaluation, 
both c3c and c4 were slightly decreased 
(c3c: 0.62 g/l, c4: 0.1 g/l). The following 
treatment was implemented: PD (16 days), 
synchronized intermittent mandatory ven-
tilation - siMV (30 days), total parenteral 
nutrition, wide spectrum of antibiotics, anti-
hypertensive treatment, numerous transfu-
sions of red blood cells (rBc), fresh frozen 
plasma (FFP) and due to a decreased level 
of igg – iVig infusions. after 42 days spent 
in Picu, there was a gradual recovery in 
the general patient condition and kidney 
function, but the girl remained severely 
hypertensive, requiring multiple antihyper-
tensive regimens. The patient was treated 
with acei with good resolution of proteinu-
ria and mild persisting hematuria. at the 
age of one year, during an upper respira-
tory tract infection, there occurred a relap-
se of ahus (scr: 150 umol/l, lDh: 2976 
u/l, platelet number: 53.000 /ul, hb: 62 g/l, 
nephrotic range proteinuria up to 14.0 g/l), 
which was treated with FFP infusions with 
a very moderate response lasting four we-
eks. since then, during viral infections of 
the respiratory tract, the patient presented 
twice with transient proteinuria up to 2.5 g/l 
that lasted for a few days and decreased 
spontaneously to the opalescence level 
after the infection terminated. at the last 
follow-up, the patient who was at the time 
2 years old had normal kidney function and 
no proteinuria, but mild erythrocyturia and 
hypertension requiring four antihypertensi-
ve medications in maximum doses. a deta-
iled complement diagnostic workup proved 
the normal levels of the complement acti-
vation products, but also identified a homo-
zygous variation causing early stop codon 
in the Dgke gene (c.966g>a (exon 6), 
p.w322*).
There are also forms of hus that inclu-
de cases triggered by neuraminidase-pro-
ducing pathogens, such as streptococcus 
pneumoniae (strep-hus). This is not an 
atypical form of hus, but due to a high 
mortality rate and complicated clinical co-
urse it is worth mentioning. The data in the 
literature suggest that severe complement 
dysregulation and consumption accompa-
ny the progress of invasive pneumococcal 
disease-associated strep-hus and gene-
tic variations of complement genes may 
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contribute to the development of this com-
plication in some proportion of the affected 
patients [13].
here, we present a case (BB) of a 4 –
year-old previously healthy boy born of he-
althy unrelated parents that was admitted 
to pediatric pulmonology ward in a good 
general condition with lobar pneumonia. 
after a few days of antibiotic treatment, 
his condition deteriorated and he needed 
intubation and siMV for 17 days. During 
his Picu stay, he developed hus (scr: 
259 umol/l, BuN: 44.2 mmol/l, lDh: 20832 
u/l, platelet count: 21.000/ul, hb: 65 g/l, 
proteinuria: 14.0 g/l). The inflammatory 
markers were positive (c-reactive prote-
in - crP: 229.6 mg/l, procalcitonin – PcT: 
45.6 mg/l). as the direct antiglobulin test 
assessed six days after the introduction 
of antibiotics was slightly positive and the 
blood culture and tracheal-bronchial aspi-
rate were both positive for streptococcus 
pneumoniae, the patient did not receive 
any FFP infusions. For 11 days, there was 
oligo-anuria and for six days, the patient 
required continuous renal replacement 
therapy (crrT). on the 12-th day of the 
Picu stay, he developed pneumothorax 
that required drainage. in the initial com-
plement evaluation, there was only slightly 
decreased c4 (0.09 g/l), whereas aP com-
ponents were within the reference ranges. 
a detailed complement diagnostic workup 
proved the normal levels of the comple-
ment activation products, except the eleva-
tion of cFB (204%), terminal complement 
complex (sc5b-9: 482 ng/ml, ref. 110-252 
ng/ml) and c3a anaphylatoxin (467 ng/ml, 
ref. 70-270 ng/ml). of note was the eleva-
tion of complement factor B antigen that 
was also observed in both parents of the 
patient. at the last follow-up, four months 
after hospitalization, the patient is in a very 
good condition with normal kidney function, 
without proteinuria, erythrocyturia and hy-
pertension.  
Despite these advances in our under-
standing of the molecular basis of ahus, 
no genetic defect has yet been found in 
one-half of ahus patients, and incomple-
te penetrance of the disease in individuals 
carrying factor h, factor i or McP muta-
tions is relatively frequent, suggesting the 
existence of additional genetic factors that 
predispose to ahus [14]. an example of 
such a patient may be our case presen-
ted below, where no abnormalities were 
found either in the complement system or 
in genetic tests, although this patient mi-
ght be considered as presenting with se-
condary form of hus due to concomitant 
infection. Nevertheless, due to the severe 
clinical course of the disease, the authors 
decided to present this case in this survey. 
a 10-month-old girl (hr) presented in our 
Department with high fever, urinary tract 
infection (uTi), without preceding diarrhea. 
in a local hospital, sepsis and aki were 
diagnosed. in our center, the child was in 
a severe clinical condition, apathetic, hypo-
volemic, oliguric with normal BP and no pe-
techiae. laboratory tests confirmed hus 
(platelet number: 17 000/ul, BuN: 35.4 
mmol/l, scr: 283 umol/l, lDh: 3521 u/l, 
proteinuria: 12 g/l, erythrocyturia: 20-30 
rBc/hpf), elevated inflammatory markers 
(crP: 74 mg/l, PcT: 12.1 ng/ml) and ab-
normalities in the coagulation system (ele-
vated D-dimer and fibrinogen levels). The 
blood culture was positive for escherichia 
coli (non ePec), none of stool cultures was 
positive, direct antiglobulin test was nega-
tive. The broad spectrum of antibiotics, 
rBc, albumin, FFP, and iVig infusions to-
gether with diuretics were introduced, but 
without satisfactory urine output response. 
in the face of failure of the conservative 
treatment, the PD for 4 days was initiated, 
which was complicated with massive le-
akage and malfunction of the catheter with 
necessity of its exchange. after two weeks, 
the platelet number was normalized, and 
renal function improved after three weeks. 
hypertension, malnutrition and massive 
proteinuria were observed as complica-
tions of the hus episode. after one year of 
follow-up, the child presented with one se-
vere episode of uTi, egFr reached about 
70 ml/min/1.73m2, with urine protein to uri-
ne creatinine ratio of 0.56 [mg%/mg%] on 
a small dose of acei treatment. The deta-
iled complement research indicated secon-
dary (to infection) activation of the classic 
(decreased total complement activity of the 
classic pathway: 28 ch50/ml (ref. 48-103 
ch50/ml) and c1q ag: 35 mg/l (ref. 60-
180 mg/l)) and alternative (decreased total 
complement activity of the alternative pa-
thway: 60 % (ref. 70-105%) and c3c: 0.85 
g/l) complement pathway. Nevertheless, no 
mutations potentially responsible for ahus 
were detected. other immunological tests 
were also within the normal limits.
Discussion
The risk of death or eskD during ahus 
episodes is variable, depending on the ba-
sic causes. in a case of Dgke, it is 7% in 
the first month up to five years; while ckD 
grade 4–5 occurs at 20–25 years [9]. on 
the other hand, in case of McP it is 17% 
and 0 %, respectively, although in patients 
with McP mutation, the presence of muta-
tions in other genes increases the risk of 
progression to eskD as compared to pa-
tients with isolated McP mutation [15].
The knowledge of the underlining ge-
netic defect and its functional consequen-
ces is of utmost importance for patients’ 
management, especially when the decision 
for transplantation must be made, as the 
highest risk factor for ahus recurrence is 
the presence of cFh, c3 or cFB mutations 
(approximately 80%) and 50% in patients 
with cFi mutation, as compared to appro-
ximately 20% in patients with no identified 
complement mutation [2,16]. The recurren-
ce risk is low in anti - cFh antibody ahus if 
the antibody titer is low at the time of trans-
plantation, while it is substantial if the titer 
is elevated [17, 18, 19, 20, 21]. The risk of 
post-transplant recurrence in patients with 
isolated McP mutation has been shown 
to be lower than 10 % [15], while no post-
-transplant recurrence has been observed 
in patients with Dgke mutation [9]. ac-
cording to the literature, the complement 
regulatory treatment is in this specific mu-
tation (Dgke) ineffective; however, renal 
transplantation may be successful without 
the risk of relapse [12]. The screening for 
Dgke mutation should be performed in all 
children with onset of ahus before the age 
of two years [9,10,11].
according to the european Pediatric 
study group for hus guidelines from 2009, 
the first line therapy in ahus is to initiate 
TPe within 24 hours of the diagnosis. ho-
wever, in 2012, the French study group for 
ahus/c3g [22], and in 2015 - campistol el 
al. [23] in a consensus document recom-
mend eculizumab as the first line therapy 
in ahus in children. 
it is of utmost importance to collect and 
store blood samples (for eDTa, eDTa pla-
sma, citrate plasma and serum) from a pa-
tient before any treatment implementation, 
with purpose of specialized  diagnostic 
workup.     
eculizumab is a monoclonal humani-
zed antibody inhibiting c5 activation and 
the formation of the membrane attack 
complex, responsible for damage to self-
-structures in ahus. in many prospective 
studies with ahus patients, eculizumab 
effectively prevented the TMa process and 
was associated with long-term significant 
hematological and renal function improve-
ments [23,24]. 
according to the literature, eculizumab 
is recommended as the early-use agent 
for ahus in pediatric and adult patients 
with clinically suspected ahus in native 
and transplanted kidneys (including ahus 
recurrence treatment and ahus prophyla-
xis). Furthermore, eculizumab should be 
considered in patients with secondary TMa 
refractory to regular treatment [23]. accor-
ding to walle et al. [24], patients with ahus 
derive greater and more sustained egFr 
recovery benefit from treatment with eculi-
zumab when the therapy is started earlier. 
however, while planning chronic treatment 
in a TMa patient, one should remember 
that there are two situations when eculizu-
mab is definitely not the first line therapy: 
the TTP cases [25, 26] and the cases cau-
sed by Dgke mutation(s) [9].
currently, there are no trustworthy re-
commendations in the literature concer-
ning the right treatment duration with eculi-
zumab and the terms of its safe withdrawal, 
though increasing experience with the drug 
use will help better define this issue as well 
as other treatment strategies in the future 
[23]. Moreover, making the decision abo-
ut eculizumab treatment one must keep in 
mind the necessity of antibiotic prophylaxis 
implementation against encapsulated bac-
teria (among others: Neisseria meningitidis 
and streptococcus pneumoniae) as well as 
realization of targeted vaccinations at ear-
liest convenience.  
Conclusion 
The diagnosis of TMa is challenging 
and is based mainly on the exclusion of 
aDaMTs13 deficient TTP and hus cau-
sed by shiga toxin. in case of thrombocy-
topenia and concurrent pneumonia in diffe-
rential diagnosis apart from disseminated 
intravascular coagulation one always sho-
248
uld acknowledge strep-hus. Furthermore, 
at present, definitive exclusion or confirma-
tion of a complement-related genetic de-
fect is time-consuming, very expensive and 
not universally possible. Nevertheless, the 
complexity of TMa, and the importance of 
the complete differential diagnostic workup 
in all non-shiga toxin-associated hus ca-
ses due to the high risk of developing ckD 
or eskD, the risk of ahus relapse (both 
in native or transplanted kidneys) and po-
tential prolonged eculizumab treatment is 
highlighted by the present case histories. 
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